Want to see BLCO full AI Analyst Report?
BLCO Stock Chart & Stats
$17.25
$0.11(0.68%)
At close: 4:00 PM EDT
$17.25
$0.11(0.68%)
Day’s Range― - ―
52-Week Range$14.44 - $18.92
Previous Close$16.28
Volume696.90K
Average Volume (3M)473.62K
Market Cap
$6.05B
Enterprise Value$10.72B
Total Cash (Recent Filing)$367.00M
Total Debt (Recent Filing)$5.12B
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Oct 28, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding357,165,250
10 Day Avg. Volume719,562
30 Day Avg. Volume473,621
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)0.94
Price to Sales (P/S)1.18
P/FCF Ratio-91.56
Enterprise Value/Market Cap1.77
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit3.52
Enterprise Value/Ebitda14.45
Forecast
1Y Price Target
$20.56Price Target Upside19.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.79
Revenue Forecast (FY)$5.49B
Bulls Say, Bears Say
Bulls Say
Broad-Based Revenue GrowthGrowth is spread across all three operating segments rather than relying on one product or channel. This breadth supports more durable revenue expansion, improves portfolio resilience, and gives the company multiple avenues to sustain momentum over the next several quarters.
Margin And Cash-Flow ImprovementHigher EBITDA and positive free cash flow indicate that revenue growth is increasingly converting into operating economics. Continued productivity gains and favorable premium mix can support reinvestment, debt reduction, and stronger financial flexibility if the improvement persists.
Diversified Product InnovationThe company is strengthening its portfolio through premium surgical products, growing pharmaceutical brands, and continued research investment. This combination can improve mix, expand future treatment options, and reinforce competitive positioning across several eye-health markets.
Bears Say
Elevated Leverage And Interest BurdenMeaningful leverage and high interest expense consume a substantial portion of operating cash generation. Although deleveraging has begun, the balance sheet remains less flexible, potentially constraining acquisitions, innovation spending, and resilience if operating performance weakens.
Persistent Net LossesNegative earnings and returns show that improved cash generation has not yet translated into durable bottom-line profitability. This limits internal capital compounding and indicates that interest, operating, or other costs remain significant obstacles to sustained shareholder value creation.
Pipeline And Regulatory Execution RiskSeveral growth opportunities depend on clinical outcomes, regulatory submissions, and approvals that have not yet been completed. Delays or unfavorable results could postpone revenue contributions and leave the company more dependent on its existing commercial portfolio.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $14.44 and its highest was $18.91 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is $6.05B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Oct 28, 2026 which is in 6 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Jul 29, 2026. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.154 by -$0.004.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.21.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 357,165,250 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.15 in its last earnings report, missing expectations of $0.154. Following the earnings report the stock price went down -2.468%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in BLCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch + Lomb Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.56 (19.16% Upside)
$20.56 (19.16% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 60%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.91%
12-Months-Change
Fundamentals
Return on Equity
-2.67%
Trailing 12-Months
Asset Growth
0.20%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
BLCO Company Deck
BLCO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum across revenue, margin expansion, cash generation and deleveraging. Broad-based growth across segments (Pharmaceuticals, Surgical, Vision Care), robust adjusted EBITDA growth, raised guidance and continued R&D investment were emphasized as evidence that the three-year plan is on track. Notable risks include elevated leverage and interest expense, macro/currency sensitivity (consumer demand tied to gas prices), ongoing regional disruptions (e.g., strikes), competitive dynamics in surgical and dry eye markets, and several important clinical and regulatory milestones still pending. Overall, the positives in growth, margins, cash flow and guidance upgrades substantially outweigh the outlined risks.View all BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
$20.56
▲(19.16% Upside)
Technical Analysis
AptarGroup
―
Baxter International
―
Cooper Co
―
Staar Surgical
―
West Pharmaceutical Services
―
Ownership Overview
0.84% Insiders
0.43% Mutual Funds
0.11% Other Institutional Investors
98.54% Public Companies and
Individual Investors